Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135122 | 0.87 | CHEK1 (0.60) | NR4A2KDM4EAPAF1RECQLCASP6 | |
| SCHEMBL3996761 | 0.86 | MCL1 (0.59) | NR1H4KDM4EAPAF1RECQLCASP6 | |
| SCHEMBL13955900 | 0.86 | NR1H4 (0.50) | NR4A2NR1H4KDM4EAPAF1RECQL | |
| SCHEMBL31042567 | 0.85 | SLC6A4 (0.54) | KDM4EACLYKMT2AMEN1POLB | |
| SCHEMBL24302512 | 0.85 | NR1H4 (0.58) | NR1H4KDM4EAPAF1RECQLCASP6 | |
| SCHEMBL70440 | 0.84 | NR4A2 (0.59) | NR4A2KDM4EMCL1EGFRKMT2A | |
| SCHEMBL14252250 | 0.84 | NR4A2 (0.59) | NR4A2KDM4EMCL1EGFRKMT2A | |
| SCHEMBL6536426 | 0.84 | NR1H4 (0.61) | NR1H4KDM4EAPAF1RECQLCASP6 | |
| SCHEMBL29717090 | 0.83 | NR1H4 (0.53) | NR1H4KDM4EAPAF1RECQLCASP6 | |
| SCHEMBL24302492 | 0.83 | NR1H4 (0.53) | NR1H4KDM4EAPAF1RECQLCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598725-A | Method for preparing biaryl compound by palladium-catalyzed desulfonyl chloride removal | 平湖石化有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2325651-A2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-13 | — | — | US | disclosed |
| US-7560488-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | NR4A2 3598/4885NR1H4 1381/4885KDM4E 2614/4885 |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | NR4A2 3683/4885NR1H4 3013/4885KDM4E 4518/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | NR4A2 3683/4885NR1H4 3013/4885KDM4E 4518/4885 |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | NR4A2 3683/4885NR1H4 3013/4885KDM4E 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.